Vaniprevir (Hepatitis C Virus)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 Unmet Need: Treatment Tolerability 23
6.2.2 Unmet Need: Efficacy 23
6.2.3 Unmet Need: Disease Awareness 24
6.2.4 Unmet Need: Treatment Cost 25
6.2.5 Unmet Need: Shorter Treatment Duration 25
6.2.6 Unmet Need: Simplified Treatment Regimens 26
6.3 Unmet Needs Gap Analysis 26
6.4 Opportunities 27
6.4.1 Opportunity: Pan-genotypic HCV Regimen 27
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 27
6.4.3 Opportunity: Involvement of Immune System 28
7 Pipeline Assessment 29
7.1 Overview 29
7.2 Promising Drugs in Clinical Development 30
8 Vaniprevir 32
8.1 Overview 32
8.2 Efficacy 33
8.3 Safety 34
8.4 Dosing and Formulation 34
8.5 Potential Clinical Positioning 34
8.6 Potential Commercial Positioning 34
8.7 Pricing and Reimbursement 35
8.8 SWOT Analysis 35
8.9 Forecast 36
9 Appendix 38
9.1 Bibliography 38
9.2 Abbreviations 40
9.3 Methodology 41
9.4 Forecasting Methodology 41
9.4.1 Percent Drug-Treated Patients 41
9.4.2 Patient Warehousing 42
9.4.3 General Pricing Assumptions 42
9.4.4 Generic Erosion 43
9.4.5 Pricing of Pipeline Agents 43
9.5 Physicians and Specialists Included in this Study 44
9.6 Survey of Prescribing Physicians 46
9.7 About the Authors 47
9.7.1 Author 47
9.7.2 Global Head of Healthcare 47
9.8 About GlobalData 48
9.9 Contact Us 48
9.10 Disclaimer 48